| Year |
Citation |
Score |
| 2019 |
Sebti SM, Kazi A, Xiang S, Yang H, Chen L, Kennedy P, Ayaz M, Fletcher S, Cummings C, Lawrence HR, Beato F, Kang Y, Kim MP, Delitto A, Underwood PW, et al. Dual farnesyl and geranylgeranyl transferase inhibitor thwarts mutant KRAS-driven patient-derived pancreatic tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31227505 DOI: 10.1158/1078-0432.Ccr-18-3399 |
0.429 |
|
| 2018 |
McDaniel NK, Cummings CT, Iida M, Hulse J, Pearson HE, Vasileiadi E, Parker RE, Orbuch RA, Ondracek OJ, Welke NB, Kang GH, Davies KD, Wang X, Frye SV, Earp HS, et al. MERTK mediates intrinsic and adaptive resistance to AXL-targeting agents. Molecular Cancer Therapeutics. PMID 30093568 DOI: 10.1158/1535-7163.Mct-17-1239 |
0.686 |
|
| 2015 |
Cummings CT, Zhang W, Davies KD, Kirkpatrick GD, Zhang D, DeRyckere D, Wang X, Frye SV, Earp HS, Graham DK. Small molecule inhibition of MERTK is efficacious in non-small cell lung cancer models independent of driver oncogene status. Molecular Cancer Therapeutics. PMID 26162689 DOI: 10.1158/1535-7163.Mct-15-0116 |
0.669 |
|
| 2014 |
Cummings CT, Linger RM, Cohen RA, Sather S, Kirkpatrick GD, Davies KD, DeRyckere D, Earp HS, Graham DK. Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer. Oncotarget. 5: 10434-45. PMID 25372020 DOI: 10.18632/Oncotarget.2142 |
0.652 |
|
| 2014 |
Morgan MJ, Gamez G, Menke C, Hernandez A, Thorburn J, Gidan F, Staskiewicz L, Morgan S, Cummings C, Maycotte P, Thorburn A. Regulation of autophagy and chloroquine sensitivity by oncogenic RAS in vitro is context-dependent. Autophagy. 10: 1814-26. PMID 25136801 DOI: 10.4161/Auto.32135 |
0.344 |
|
| 2014 |
Zhang W, DeRyckere D, Hunter D, Liu J, Stashko MA, Minson KA, Cummings CT, Lee M, Glaros TG, Newton DL, Sather S, Zhang D, Kireev D, Janzen WP, Earp HS, et al. UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. Journal of Medicinal Chemistry. 57: 7031-41. PMID 25068800 DOI: 10.1021/Jm500749D |
0.626 |
|
| 2014 |
DeRyckere DA, Hill AA, Wang X, Zhang W, Stashko MA, Sather S, Cummings C, Kireev D, Janzen WP, Frye SV, Earp HS, Graham DK. Abstract 1740: Development of a novel small molecule MER tyrosine kinase inhibitor with therapeutic activity in cell culture and mouse models of acute lymphoblastic leukemia Cancer Research. 74: 1740-1740. DOI: 10.1158/1538-7445.Am2014-1740 |
0.706 |
|
| 2013 |
Zhang W, Zhang D, Stashko MA, DeRyckere D, Hunter D, Kireev D, Miley MJ, Cummings C, Lee M, Norris-Drouin J, Stewart WM, Sather S, Zhou Y, Kirkpatrick G, Machius M, et al. Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors. Journal of Medicinal Chemistry. 56: 9683-92. PMID 24195762 DOI: 10.1021/Jm401387J |
0.688 |
|
| 2013 |
Christoph S, Deryckere D, Schlegel J, Frazer JK, Batchelor LA, Trakhimets AY, Sather S, Hunter DM, Cummings CT, Liu J, Yang C, Kireev D, Simpson C, Norris-Drouin J, Hull-Ryde EA, et al. UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. Molecular Cancer Therapeutics. 12: 2367-77. PMID 23997116 DOI: 10.1158/1535-7163.Mct-13-0040 |
0.671 |
|
| 2013 |
Cummings CT, Deryckere D, Earp HS, Graham DK. Molecular pathways: MERTK signaling in cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5275-80. PMID 23833304 DOI: 10.1158/1078-0432.Ccr-12-1451 |
0.652 |
|
| 2013 |
Liu J, Zhang W, Stashko MA, Deryckere D, Cummings CT, Hunter D, Yang C, Jayakody CN, Cheng N, Simpson C, Norris-Drouin J, Sather S, Kireev D, Janzen WP, Earp HS, et al. UNC1062, a new and potent Mer inhibitor. European Journal of Medicinal Chemistry. 65: 83-93. PMID 23693152 DOI: 10.1016/J.Ejmech.2013.03.035 |
0.693 |
|
| 2012 |
Maycotte P, Aryal S, Cummings CT, Thorburn J, Morgan MJ, Thorburn A. Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy. Autophagy. 8: 200-12. PMID 22252008 DOI: 10.4161/Auto.8.2.18554 |
0.385 |
|
| 2010 |
Fletcher S, Keaney EP, Cummings CG, Blaskovich MA, Hast MA, Glenn MP, Chang SY, Bucher CJ, Floyd RJ, Katt WP, Gelb MH, Van Voorhis WC, Beese LS, Sebti SM, Hamilton AD. Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents. Journal of Medicinal Chemistry. 53: 6867-88. PMID 20822181 DOI: 10.1021/Jm1001748 |
0.328 |
|
| 2009 |
Hast MA, Fletcher S, Cummings CG, Pusateri EE, Blaskovich MA, Rivas K, Gelb MH, Van Voorhis WC, Sebti SM, Hamilton AD, Beese LS. Structural basis for binding and selectivity of antimalarial and anticancer ethylenediamine inhibitors to protein farnesyltransferase. Chemistry & Biology. 16: 181-92. PMID 19246009 DOI: 10.1016/J.Chembiol.2009.01.014 |
0.328 |
|
| 2008 |
Fletcher S, Cummings CG, Rivas K, Katt WP, Hornéy C, Buckner FS, Chakrabarti D, Sebti SM, Gelb MH, Van Voorhis WC, Hamilton AD. Potent, Plasmodium-selective farnesyltransferase inhibitors that arrest the growth of malaria parasites: structure-activity relationships of ethylenediamine-analogue scaffolds and homology model validation. Journal of Medicinal Chemistry. 51: 5176-97. PMID 18686940 DOI: 10.1021/Jm800113P |
0.312 |
|
| 2006 |
Glenn MP, Chang SY, Hornéy C, Rivas K, Yokoyama K, Pusateri EE, Fletcher S, Cummings CG, Buckner FS, Pendyala PR, Chakrabarti D, Sebti SM, Gelb M, Van Voorhis WC, Hamilton AD. Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites. Journal of Medicinal Chemistry. 49: 5710-27. PMID 16970397 DOI: 10.1021/Jm060081V |
0.346 |
|
| Show low-probability matches. |